The Gilead Research Scholars Program in Solid Tumors 2026 supports early-career investigators conducting independent basic or clinical research addressing unmet needs in breast, endometrial, ovarian, or small cell lung cancer.
Gilead will provide a minimum of three awards of $180,000 each over two years. The first-stage application consists of a one-page Specific Aims submission due November 13, 2026 at 11:59 PM PT.
Eligibility Criteria
- Applicants must hold an MD, DO, PhD, or equivalent degree.
- Candidates must be junior faculty meeting the NIH definition of an Early Stage Investigator.
- The initial faculty appointment must have occurred within the previous 7 years.
- Applicants must have institutional support allowing at least 30% professional time for research.
- Applicants who already hold major NIH awards such as an R01, P01, or U01 as PI are generally ineligible.
- Fellows are generally not eligible.
- Applicants must be U.S. citizens/permanent residents or hold an appropriate visa allowing them to complete the two-year research period in the U.S.
Funding Details
- Award: $180,000.
- Duration: 2 years.
- Minimum number of awards: 3.
Deadline
- Round 1 Specific Aims deadline: November 13, 2026 at 11:59 PM PT.
- Round 1 decisions: By February 2027.
- Invited detailed proposal deadline: March 10, 2027 at 11:59 PM PT.
- Final decisions: May 2027.
Further Information
- The research must be achievable within the two-year award period.
- Applications are independently scientifically reviewed.
- Official program page: View the official Gilead Research Scholars program